Real-life experience with non-vitamin K antagonist oral anticoagulants versus warfarin in patients undergoing elective cardioversion of atrial fibrillation.
Saga Itäinen-StrömbergAnna-Mari HekkalaAapo L AroTuija VasankariKari Eino Juhani AiraksinenMika LehtoPublished in: Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc (2020)
In this real-life study, the rates of thromboembolic and bleeding complications were low in AF patients undergoing ECV. Patients receiving NOAC therapy had a shorter time to cardioversion and continued their anticoagulation therapy more often than patients on warfarin.
Keyphrases
- atrial fibrillation
- oral anticoagulants
- patients undergoing
- left atrial
- catheter ablation
- direct oral anticoagulants
- left atrial appendage
- end stage renal disease
- heart failure
- chronic kidney disease
- ejection fraction
- newly diagnosed
- percutaneous coronary intervention
- peritoneal dialysis
- prognostic factors
- risk factors
- patient reported outcomes
- coronary artery disease
- acute coronary syndrome
- mesenchymal stem cells